FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Salzmann Peter					2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]									(Check	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last)	(First)	•	ddle)			3. Date of Earliest Transaction (Month/Day/Year) 09/28/2022								X	Officer (g below)			Other (specify below)			
C/O IMMUNOVANT, INC. 320 W 37TH STREET, 6TH FLOOR (Street) NEW YORK NY 10018					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indiv	. Individual or Joint/Group Filing (Check Applicable Line)						
(City)	(State)	(Zi _l	o) 																		
		Та	ble I - Nor	n-Deri	ivativ	e Se	curitie	s Acqı	uired, l	Disp	osed of,	or I	Benefic	cially Ow	ned						
Date					nth/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)					ties Acquired (A) or I Of (D) (Instr. 3, 4 an			5. Amount Securities Beneficially Following	y Owned Reported	Form:	Direct (D) irect (I) 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount		(A) or (D)	Price	Transactio (Instr. 3 and				(Instr. 4)		
Common Stock ⁽¹⁾ 09/2						28/2022			S		1,605	5	D	\$4.67	1,000),746		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution			Date, Transac Code (In				ive ies ed (A) osed of	6. Date Exerci Expiration Dat (Month/Day/Ye		e Securities Under		derlying curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code V		(A)	(D)			Expiration Date	Title		Amount or Number of Shares		(Instr. 4)		7			

Explanation of Responses:

1. On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 2,760 of these RSUs vested on September 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

Remarks:

/s/ Eva Renee Barnett, attorney-infact for Peter Salzmann 09/29/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.